BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Transcription profiling of mouse DBA/2J animals with Streptozotocin-induced diabetes treated with rosiglitazone reduces diabetic neuropathy

Dataset: Transcription profiling of mouse DBA/2J animals with Streptozotocin-induced diabetes treated with rosiglitazone reduces diabetic neuropathy

Diabetic Neuropathy (DN) is a common complication of diabetes. Currently, there is no drug treatment to prevent or slow the development...

Registered by ArrayExpress Uploader
View Dataset

Diabetic Neuropathy (DN) is a common complication of diabetes. Currently, there is no drug treatment to prevent or slow the development of DN. Rosiglitazone (Rosi) is a potent insulin sensitizer and may also slow the development of DN by a mechanism independent of its effect on hyperglycemia. A two by two design was used to test the effect of Rosi treatment on the development of DN. Streptozotocin-induced diabetic DBA/2J mice were treated with Rosi. DN and oxidative stress were quantified, and gene expression was profiled using the Affymetrix Mouse Genome 430 2.0 microarray platform. An informatics approach identified key regulatory elements activated by Rosi. Diabetic DBA/2J mice developed severe hyperglycemia, DN and elevated oxidative stress. Rosi treatment did not affect hyperglycemia but did reduce oxidative stress and prevented development of thermal hypoalgesia. Two novel transcription factor binding modules were identified that may control genes correlated to changes in DN following Rosi treatment: SP1F_ZBPF and EGRF_EGRF. Rosi treatment reduced oxidative stress and DN independent of its insulin sensitizing effects. Gene expression profiling identified two novel targets activated by Rosi treatment. These targets may be useful in designing drugs with the same efficacy as Rosi in treating DN but with fewer undesirable effects. Experiment Overall Design: There were 4 groups: Experiment Overall Design: Control Experiment Overall Design: Control + Rosi Experiment Overall Design: Diabetic (Type 1) Experiment Overall Design: Diabetic + Rosi Experiment Overall Design: Affymetrix chips were run on five mice from each group. One chip (in the Control group) failed quality control measures and was excluded.

Species:
mouse

Samples:
19

Source:
E-GEOD-11343

Updated:
Dec.12, 2014

Registered:
Nov.10, 2014


Factors: (via ArrayExpress)
Sample
GSE11343GSM286431
GSE11343GSM286432
GSE11343GSM286433
GSE11343GSM286434
GSE11343GSM286436
GSE11343GSM286159
GSE11343GSM286160
GSE11343GSM286163
GSE11343GSM286165
GSE11343GSM286437
GSE11343GSM286438
GSE11343GSM286591
GSE11343GSM286592
GSE11343GSM286593
GSE11343GSM286169
GSE11343GSM286173
GSE11343GSM286176
GSE11343GSM286178
GSE11343GSM286430

Tags

  • diabetic neuropathy
  • genome
  • hyperglycemia
  • insulin
  • neuropathy

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2022 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use